chenodeoxycholic acid has been researched along with Cardiovascular Diseases in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Costantino, G; Fiorucci, S; Pellicciari, R | 1 |
| Drew, L | 1 |
| Baldelli, F; Cipriani, S; D'Amore, C; Distrutti, E; Fiorucci, S; Mencarelli, A; Palladino, G; Renga, B | 1 |
1 review(s) available for chenodeoxycholic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Farnesoid X receptor: from structure to potential clinical applications.
Topics: Animals; Bile Acids and Salts; Binding Sites; Cardiovascular Diseases; Diabetes Mellitus, Type 2; DNA-Binding Proteins; Humans; Insulin Resistance; Ligands; Models, Molecular; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2005 |
2 other study(ies) available for chenodeoxycholic acid and Cardiovascular Diseases
| Article | Year |
|---|---|
Drug development: Sprint finish.
Topics: Animals; Biotechnology; Cardiovascular Diseases; Chenodeoxycholic Acid; Clinical Trials as Topic; Drug Discovery; Drug Industry; Hepatitis C; Humans; Liver Cirrhosis; Mice; Molecular Targeted Therapy; Non-alcoholic Fatty Liver Disease | 2017 |
FXR activation improves myocardial fatty acid metabolism in a rodent model of obesity-driven cardiotoxicity.
Topics: Acyl-CoA Oxidase; Animals; Apoptosis; Bile Acids and Salts; Blood Glucose; Cardiovascular Diseases; Chenodeoxycholic Acid; Dyslipidemias; Fibrosis; Hyperinsulinism; Hyperlipidemias; Insulin Resistance; Isoxazoles; Lipid Metabolism; Liver; Myocardium; Obesity; PPAR alpha; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Rats; Rats, Zucker; Receptors, Cytoplasmic and Nuclear; Risk Factors; RNA, Messenger; Triglycerides | 2013 |